Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb;28(2):140-149.
doi: 10.1111/iju.14406. Epub 2020 Oct 27.

Epigenetic modifications in prostate cancer

Masahiro Sugiura  1   2 , Hiroaki Sato  1   2 , Manato Kanesaka  1   2 , Yusuke Imamura  1 , Shinichi Sakamoto  1 , Tomohiko Ichikawa  1 , Atsushi Kaneda  2
Affiliations
Review

Epigenetic modifications in prostate cancer

Masahiro Sugiura et al. Int J Urol. 2021 Feb.

Abstract

Prostate cancer is a major cause of cancer-related deaths among men worldwide. In addition to genomic alterations, epigenetic alterations accumulated in prostate cancer have been elucidated. While aberrant deoxyribonucleic acid hypermethylation in promoter CpG islands inactivates crucial genes associated with deoxyribonucleic acid repair, cell cycle, apoptosis or cell adhesion, aberrant deoxyribonucleic acid hypomethylation can lead to oncogene activation. Acetylation of histone is also deregulated in prostate cancer, which could cause aberrant super-enhancer formation and activation of genes associated with cancer development. Deregulations of histone methylation, such as an increase of trimethylation at position 27 of histone H3 by enhancer of zeste homolog2 overexpression, or other modifications, such as phosphorylation and ubiquitination, are also involved in prostate cancer development, and inhibitors targeting these epigenomic aberrations might be novel therapeutic strategies. In this review, we provide an overview of epigenetic alterations in the development and progression of prostate cancer, focusing on deoxyribonucleic acid methylation and histone modifications.

Keywords: DNA methylation; epigenetic alterations; epigenetics; histone modifications; prostate cancer.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016; 66: 7-30.
    1. Kaminska K, Nalejska E, Kubiak M et al. Prognostic and predictive epigenetic biomarkers in oncology. Mol. Diagn. Ther. 2019; 23: 83-95.
    1. Yadav SS, Stockert JA, Hackert V, Yadav KK, Tewari AK. Intratumor heterogeneity in prostate cancer. Urol. Oncol. 2018; 36: 349-60.
    1. Robinson D, Van Allen EM, Wu YM et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015; 161: 1215-28.
    1. Cancer Genome Atlas Research N. The molecular taxonomy of primary prostate cancer. Cell 2015; 163: 1011-25.

LinkOut - more resources